Vaccinex, Inc. Stock

VCNX

US9186403013

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:20:04 2026-08-03 EDT			5-day change	1st Jan Change
1.150 ^USD	+35.98%		-2.54%	+6.93%

07-08	Vaccinex, Inc. Reports New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in Alzheimer?s Disease	CI
12-23	Vaccinex, Inc. Enters into a $60 Million Revenue Sharing Agreement with Pepinemab Development Venture, LP	CI

News in other languages: Vaccinex, Inc.

23-09-25

MORNING BRIEFING - USA/Asien

More news

Managers and Directors: Vaccinex, Inc.

Manager	Title	Age	Since
Maurice Zauderer CEO	Chief Executive Officer	80	2001-03-31
Jil Sanchez DFI	Director of Finance/CFO	54	2024-03-13
Elizabeth Evans COO	Chief Operating Officer	54	2021-05-10

Director	Title	Age	Since
Maurice Zauderer BRD	Director/Board Member	80	2001-03-31
Albert Friedberg CHM	Chairman	79	2001-03-31
Jacob Frieberg BRD	Director/Board Member	69	2015-01-31

More insiders

Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimerâ€™s disease, head and neck, pancreatic and breast cancer. Its platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. Its SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including neuroinflammatory and neurodegenerative diseases and cancer. It also discovered VX5 using its ActivMAb platform. VX5 is a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, and is in preclinical development for the treatment of autoimmune disorders.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-03	US$1.150	+35.98%	2,001

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Market Cap	2.88M 2.5M 2.34M 2.14M 4.04M 274M 4.11M 27.54M 10.79M 137M 10.81M 10.57M 451M	P/E 2023	-0.21x	P/E 2024	-0.11x
Enterprise Value	1.8M 1.56M 1.46M 1.34M 2.52M 171M 2.57M 17.19M 6.73M 85.4M 6.75M 6.6M 282M	EV / Sales 2023	12.3x	EV / Sales 2024	2.56x
Free-Float	88.59%	Yield 2023 *	-	Yield 2024	-

07-08	Vaccinex, Inc. Reports New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in Alzheimer?s Disease	CI
12-23	Vaccinex, Inc. Enters into a $60 Million Revenue Sharing Agreement with Pepinemab Development Venture, LP	CI
25-05-27	Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer At Asco Annual Meeting	CI
25-04-21	Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research	CI
25-04-15	Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-04-14	Vaccinex, Inc. Auditor Raises 'Going Concern' Doubt	CI
25-03-19	Vaccinex, Inc. Announces Resignation of Bala S. Manian as A Director	CI
24-12-19	Vaccinex, Inc.(OTCPK:VCNX) dropped from S&P TMI Index	CI
24-12-17	Top Midday Decliners	MT
24-12-17	Vaccinex Stock to Be Delisted From Nasdaq	MT
24-12-16	Vaccinex, Inc.(OTCPK:VCNX) dropped from NASDAQ Composite Index	CI
24-11-18	Earnings Flash (VCNX) VACCINEX Reports Q3 Revenue $52,000	MT
24-11-14	Vaccinex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI

07-08	Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026	AQ
04-29	Vaccinex Reports 2025 Annual Financial Results	AQ
12-23	Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease	AQ
12-03	Vaccinex : CTAD 2025 Oral Communication	PU
25-05-27	Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting	AQ

1 day	+35.98%
1 week	-2.54%
Current month	+35.98%
1 month	+12.75%
3 months	+15.00%
6 months	-11.54%
Current year	+6.93%

1 week	0.85	1.18
1 month	0.85	1.29
Current year	0.34	1.5
1 year	0.31	1.5
3 years	0.25	60.88
5 years	0.25	546
10 years	0.25	2,568.3

Vaccinex, Inc. Stock

Stocks

VCNX

US9186403013

Biotechnology & Medical Research

Valuation: Vaccinex, Inc.

Chart: Vaccinex, Inc.

Latest news : Vaccinex, Inc.

Press Releases: Vaccinex, Inc.

News in other languages: Vaccinex, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Vaccinex, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/14/24	Maurice Zauderer	Other	Founder	46,153	1.6512%
11/14/24	Albert Friedberg	Other	Chairman	0	0%
11/14/24	Friedberg Mercantile Group Ltd. /Friedberg Family/	Other	Company	615,402	22.0164%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VACCINEX, INC.	+35.98%	-2.54%	+45.59%	-98.14%	2.26M
WUXI APPTEC CO., LTD.	+0.05%	+2.80%	+38.17%	+74.12%	56.54B
ARGENX SE	-3.06%	-8.56%	+23.62%	+58.73%	53.6B
BIONTECH SE	+1.84%	+1.27%	-14.06%	-13.50%	22.91B
INSMED INCORPORATED	-0.15%	-6.00%	-9.42%	+344.47%	21.37B
WUXI BIOLOGICS (CAYMAN) INC.	+0.15%	-0.77%	+23.76%	-11.52%	20.27B
GENMAB A/S	-0.67%	-1.73%	+33.09%	-31.09%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.45%	-7.24%	+17.67%	+563.14%	14.75B
PHARMAESSENTIA CORPORATION	+9.91%	+2.64%	+188.84%	+326.19%	13.53B
EXELIXIS, INC.	+3.83%	-1.34%	+47.77%	+165.22%	13.33B
Average	+4.64%	-1.69%	+39.50%	+137.76%	23.39B
Weighted average by Cap.	+0.14%	-1.70%	+31.71%	+122.00%

	2023	2024
Net sales	570K 495K 462K 425K 801K 54.33M 815K 5.45M 2.14M 27.09M 2.14M 2.09M 89.36M	601K 522K 488K 448K 844K 57.28M 859K 5.75M 2.25M 28.57M 2.26M 2.21M 94.22M
Net income	-20.25M -17.6M -16.43M -15.08M -28.44M -1.93B -28.94M -194M -75.88M -963M -76.07M -74.38M -3.17B	-18.63M -16.19M -15.12M -13.88M -26.17M -1.78B -26.63M -178M -69.82M -886M -69.99M -68.44M -2.92B
Net Debt	-1.29M -1.12M -1.05M -959K -1.81M -123M -1.84M -12.32M -4.83M -61.22M -4.84M -4.73M -202M	-1.08M -940K -878K -806K -1.52M -103M -1.55M -10.35M -4.05M -51.43M -4.06M -3.97M -170M